US stock movement: Fast and Precision Pharma surged on October 2 as FDA approval and sepsis detection boosted shares

Fast & Accurate Medicine October 2 – Significant Surge Explained

Keywords: FDA clearance, sepsis detection

1. On September 28, QIAGEN announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GN Plus AMR Panel, enabling the identification of 13 Gram-negative bacterial pathogens and 18 antimicrobial resistance markers in approximately one hour.

2. On September 28, the QIAstat-Dx bloodstream infection detection panel was announced to cover 33 pathogen targets and 28 resistance markers, complementing previously FDA-cleared Gram-positive bacteria and fungal detection panels, and improving its molecular diagnostics portfolio.

(Disclaimer: This content is summarized from publicly available information by AI technology. It is for reference only and does not constitute investment advice.)